Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biofield To Submit Revamped PMA For Breast Cancer Diagnosis System

This article was originally published in The Gray Sheet

Executive Summary

Biofield is planning to make a second attempt at securing FDA approval for its Biofield Diagnostic Device following the completion of an upcoming clinical trial of the non-invasive tool to evaluate its use as an aid in breast cancer detection.

You may also be interested in...

Biofield Petitions for Less Burdensome Route For Breast Cancer Diagnostic

Biofield Corp. expects to hear from FDA within 60 days regarding a de novo petition for reclassification of its investigational breast cancer diagnostic device to Class II status

Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts